CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity

被引:70
作者
Kitagawa, K
Kunugita, N
Kitagawa, M
Kawamoto, T
机构
[1] Univ Occupat & Environm Hlth, Dept Environm Hlth, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
[2] Hamamatsu Univ Sch Med, Dept Biochem, Hamamatsu, Shizuoka 4313192, Japan
关键词
D O I
10.1074/jbc.M009432200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
By using the polymerase chain reaction technique combined with restriction enzyme fragment length polymorphism (PCR-RFLP), a novel polymorphism of CYP2A6, CYP2A6*6, was detected in 0.4% of the Japanese population. To study the enzymatic properties of the CYP2A6.6 protein with a single amino acid substitution of arginine 128 to glutamine, both this isozyme and the CYP2A6.1 protein (wild-type) were produced in insect cells using a baculovirus system. Coumarin 7-hydroxylation, which reflects CYP2A6 activity, was significantly reduced tone-eighth of normal) in cell lysate from CYP2AG*6-transfected Sf9 cells compared with that lysate from CYP2A6*1-transfected cells. To clarify the mechanism of inactivation of the CYP2A6.6 enzyme, the heme content and reduced CO difference spectrum were examined. Although CYP2A6.6 retained about one-half the heme content of CYP2A6.1, the reduced CO-bound Soret peak was completely lost. These results suggest that the inactivation of CYP2A6.6 is mainly due to disordering of the holoprotein structure rather than a failure of heme incorporation.
引用
收藏
页码:17830 / 17835
页数:6
相关论文
共 30 条
[11]   CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians [J].
Inoue, K ;
Yamazaki, H ;
Shimada, T .
ARCHIVES OF TOXICOLOGY, 2000, 73 (10-11) :532-539
[12]   The significance of the homozygous CYP2A6 deletion on nicotine metabolism:: A new genotyping method of CYP2A6 using a single PCR-RFLP [J].
Kitagawa, K ;
Kunugita, N ;
Katoh, T ;
Yang, MH ;
Kawamoto, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 262 (01) :146-151
[13]   Expression of CYP2A genes in human liver and extrahepatic tissues [J].
Koskela, S ;
Hakkola, J ;
Hukkanen, J ;
Pelkonen, O ;
Sorri, M ;
Saranen, A ;
Anttila, S ;
Fernandez-Salguero, P ;
Gonzalez, F ;
Raunio, H .
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (12) :1407-1413
[14]   METABOLISM OF [3-14C]COUMARIN TO POLAR AND COVALENTLY BOUND PRODUCTS BY HEPATIC MICROSOMES FROM THE RAT, SYRIAN-HAMSTER, GERBIL AND HUMANS [J].
LAKE, BG ;
GAUDIN, H ;
PRICE, RJ ;
WALTERS, DG .
FOOD AND CHEMICAL TOXICOLOGY, 1992, 30 (02) :105-115
[15]   THE SEQUENCE HOMOLOGIES OF CYTOCHROMES-P-450 AND ACTIVE-SITE GEOMETRIES [J].
LEWIS, DFV ;
MOEREELS, H .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1992, 6 (03) :235-252
[16]   MOLECULAR MODELING OF MEMBERS OF THE P4502A SUBFAMILY - APPLICATION TO STUDIES OF ENZYME SPECIFICITY [J].
LEWIS, DFV ;
LAKE, BG .
XENOBIOTICA, 1995, 25 (06) :585-598
[17]   3-DIMENSIONAL MODELS OF HUMAN AND OTHER MAMMALIAN MICROSOMAL P450S CONSTRUCTED FROM AN ALIGNMENT WITH P450102 (P450(BM3)) [J].
LEWIS, DFV .
XENOBIOTICA, 1995, 25 (04) :333-366
[18]   Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans [J].
Nakajima, M ;
Yamagishi, S ;
Yamamoto, H ;
Yamamoto, T ;
Kuroiwa, Y ;
Yokoi, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (01) :57-69
[19]  
Nakajima M, 1996, J PHARMACOL EXP THER, V277, P1010
[20]  
Nakajima M, 1996, DRUG METAB DISPOS, V24, P1212